

**North of Tyne, Gateshead and North Cumbria  
Area Prescribing Committee**

[www.northoftyneapc.nhs.uk](http://www.northoftyneapc.nhs.uk)

**Tuesday 19<sup>th</sup> October 2021 12:30 pm**

[Join Microsoft Teams Meeting](#)

**AGENDA**

1.	Apologies for absence	
2.	Declarations of interest	
3.	Appeals against previous decision: None	
4.	Minutes from the meeting 6/7/21 Decision summary from 6/7/21	Enc.1. Enc.2.
5.	Matters arising not on the agenda	
6.	APC Action log <ul style="list-style-type: none"> <li>• September update</li> </ul>	Enc.3.
7.	Report from the Formulary sub-group <ul style="list-style-type: none"> <li>• Draft minutes from meeting held on 9/9/21</li> </ul>	Enc.4.
8.	Incliseran NHS England and NHS Improvement letter Medicines Optimisation pack North of Tyne, Gateshead and North Cumbria APC position statement	Enc.5. Enc.6. Enc.7.
9.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> <li>• Draft minutes from meeting held on 6/9/21</li> <li>• RMOG shared care processes – integration with local guidance</li> <li>• Guidance/documents approved: <ul style="list-style-type: none"> <li>○ Methylphenidate secondary to brain injury: shared care guidance</li> <li>○ Urinary Continence Enablement Products and Devices - formulary</li> <li>○ Catheter formulary</li> <li>○ SGLT-2 Top Tips – diabetes</li> </ul> </li> <li>• Guidance to be retained with extended expiry date <ul style="list-style-type: none"> <li>○ Guideline for Monitoring of Immune Modifying Drugs in Stable Adult Patients</li> </ul> </li> </ul>	Enc.8. Enc.9. Enc.10. Enc.11. Enc.12. Enc.13.
10.	Letter from NENC LMCs to APC chairs	Enc.14.
11.	Opiate/pain management sub-group <ul style="list-style-type: none"> <li>• Update from meeting held on 16/9/21 <ul style="list-style-type: none"> <li>○ Request to change formulary status for codeine 15mg</li> </ul> </li> </ul>	Enc.15.

12.	<p><b>RMOCs</b></p> <p>To note: fourth and fifth sets of draft shared care protocols out for consultation:</p> <ul style="list-style-type: none"> <li>• Azathioprine (non-transplant)</li> <li>• Hydroxychloroquine</li> <li>• Mycophenolate mofetil (non-transplant)</li> <li>• Oral ciclosporin (non-transplant)</li> <li>• Oral and subcutaneous methotrexate (excluding cancer)</li> <li>• Sulfasalazine</li> </ul> <p>Guidance on managing requests from private providers for shared care - consultation (open to 21/10/21)</p>	<p>Email 2/8/21 &amp; 4/10/21 <a href="#">Link</a></p> <p>Enc.16.</p>
13.	<p>DHSC publication: Good for you, good for us. Good for everybody</p>	<p>Enc.17. <a href="#">Link</a></p>
14.	<p>Northern (NHS) Treatment Advisory Group (NTAG). <a href="http://ntag.nhs.uk/">http://ntag.nhs.uk/</a></p> <p>The following recommendations were updated/approved by NTAG at their meeting on the 7th September 2021 and will be available on their website:</p> <ul style="list-style-type: none"> <li>• Lurasidone (Latuda®) for the treatment of schizophrenia in adults and adolescents aged 13 years and over – updated recommendation recommending use as an option as per criteria specified in recommendation, and also including use in adolescents.</li> <li>• Daily vs on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer – updated recommendation that once daily oral 5mg tadalafil may be considered as an option for the management of erectile dysfunction following treatment for prostate cancer. Oral 2.5mg tadalafil is not recommended by NTAG for this indication on the basis of cost.</li> <li>• Buprenorphine prolonged release injection for opioid dependence – new recommendation that an alternative option for the management of opioid dependence after oral methadone and/or oral buprenorphine.</li> </ul>	<p>Enc.18.</p> <p>Enc.19.</p> <p>Enc.20.</p>
15.	<p>NICE HSTs and Technology Appraisals published since last meeting :</p> <ul style="list-style-type: none"> <li>• HST15 <a href="#">Onasemnogene abeparvovec for treating spinal muscular atrophy</a></li> <li>• TA712 <a href="#">Enzalutamide for treating hormone-sensitive metastatic prostate cancer</a></li> <li>• TA713 <a href="#">Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy</a></li> <li>• TA714 <a href="#">Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia</a>: terminated appraisal</li> <li>• TA715 <a href="#">Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed</a></li> <li>• TA716 <a href="#">Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency</a></li> <li>• TA717 <a href="#">Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies</a>: terminated appraisal</li> <li>• TA718 <a href="#">Ixekizumab for treating axial spondyloarthritis</a></li> <li>• TA719 <a href="#">Secukinumab for treating non-radiographic axial</a></li> </ul>	

	<p><a href="#">spondyloarthritis</a></p> <ul style="list-style-type: none"> <li>• TA720 <a href="#">Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma</a></li> <li>• TA721 <a href="#">Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer</a></li> <li>• TA722 <a href="#">Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement</a></li> <li>• TA723 <a href="#">Bimekizumab for treating moderate to severe plaque psoriasis</a></li> <li>• TA724 <a href="#">Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer</a> Negative appraisal</li> <li>• TA725 <a href="#">Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a></li> <li>• TA726 <a href="#">Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a></li> <li>• TA727 <a href="#">Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a></li> <li>• TA728 <a href="#">Midostaurin for treating advanced systemic mastocytosis</a></li> <li>• TA729 <a href="#">Sapropterin for treating hyperphenylalaninaemia in phenylketonuria</a></li> <li>• TA730 <a href="#">Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)</a></li> <li>• TA731 <a href="#">Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)</a></li> <li>• TA732 <a href="#">Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)</a></li> <li>• TA733 <a href="#">Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia</a></li> <li>• TA734 <a href="#">Secukinumab for treating moderate to severe plaque psoriasis in children and young people</a></li> </ul>	
16.	<p>NHS England</p> <ul style="list-style-type: none"> <li>• Specialised Services circulars <ul style="list-style-type: none"> <li>○ SSC2269: Rituximab for Immunobullous Disease (Ocular Amendment)</li> <li>○ SSC2270: Abatacept for treatment of severe treatment-resistant morphea (localised scleroderma) (adults and children 2 years and over)</li> <li>○ SSC2272: Early Access to Medicines Scheme – tepotinib as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.</li> <li>○ SSC2273: Mercaptamine hydrochloride viscous eyedrops for corneal cystine deposits in people aged 2 years and over.</li> <li>○ SSC2274: Baricitinib for use in monogenic interferonopathies (adults and children 2 years and over)</li> <li>○ SSC2278: pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement</li> <li>○ SSC2279 - Specialised Commissioning Update August 2021 to October 2021</li> <li>○ SSC2280 - NICE Technology Appraisal Final Appraisal Determination: abemaciclib with fulvestrant for treating</li> </ul> </li> </ul>	Enc.21.

	<p>hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</p> <ul style="list-style-type: none"> <li>○ SSC2282 - NICE Technology Appraisal Final Appraisal Determination - Midostaurin for treating advanced systemic mastocytosis</li> <li>○ SSC2284 - Early Access to Medicines Scheme – nivolumab as monotherapy for the treatment of advanced or recurrent gastric or gastro-oesophageal junction cancer.</li> <li>○ SSC2287 - NICE Technology Appraisal Final Appraisal Determination: apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer</li> <li>○ SSC2288 - NICE Technology Appraisal Final Appraisal Determination: apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer.</li> <li>○ SSC2289 - NICE Technology Appraisal Final Appraisal Determination: nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy.</li> <li>○ SSC2290 - NICE Technology Appraisal Final Appraisal Determination: pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer.</li> <li>○ SSC2291- NICE Technology Appraisal Consultation Document: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies</li> </ul>	
17.	<p>Chairman's action</p> <ul style="list-style-type: none"> <li>• Approval of abnormal LFT guidance – chair's approval taken in 2020 but omitted from minutes. Included here for completeness.</li> <li>• Approval of RAG status change of fidaxomicin from RED to GREEN PLUS to allow use in line with new NICE recommendations.</li> <li>• Incliseran approval as Green</li> </ul>	
18.	Any other business	
19.	<p>Date, time and venue of next meetings:</p> <p>11/1/22 12.30-3pm  5/4/22 12.30-3pm  5/7/22 12.30-3pm  11/10/22 12.30-3pm  All via Microsoft teams</p>	